Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2014 (2014), Article ID 840492, 6 pages
http://dx.doi.org/10.1155/2014/840492
Case Report

Hypochondroplasia, Acanthosis Nigricans, and Insulin Resistance in a Child with FGFR3 Mutation: Is It Just an Association?

1Department of Pediatrics, Latifa Hospital, Dubai, UAE
2Molecular Diagnostic Laboratory, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia
3Department of Pediatrics, King Faisal Specialist Hospital and Research Center, MBC 58, P.O. Box 3354, Riyadh 11211, Saudi Arabia

Received 7 July 2014; Revised 28 October 2014; Accepted 30 October 2014; Published 19 November 2014

Academic Editor: Carlo Capella

Copyright © 2014 Manal Mustafa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Vajo, C. A. Francomano, and D. J. Wilkin, “The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans,” Endocrine Reviews, vol. 21, no. 1, pp. 23–39, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Foldynova-Trantirkova, W. R. Wilcox, and P. Krejci, “Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias,” Human Mutation, vol. 33, no. 1, pp. 29–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Naski, Q. Wang, J. Xu, and D. M. Ornitz, “Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia,” Nature Genetics, vol. 13, no. 2, pp. 233–237, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Brockow, V. Steinkraus, F. Rinninger, D. Abeck, and J. Ring, “Acanthosis nigricans: a marker for hyperinsulinemia,” Pediatric Dermatology, vol. 12, no. 4, pp. 323–326, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. R. L. Barbieri, “Hyperandrogenism, insulin resistance and acanthosis nigricans: 10 Years of progress,” Journal of Reproductive Medicine, vol. 39, no. 5, pp. 327–336, 1994. View at Google Scholar · View at Scopus
  6. A. ArlanRosenbloom, S. Arslanian, S. Brink, K. Conschafter, K. L. Jones, and G. Klingensmith, “Type 2 diabetes in children and adolescents,” Diabetes Care, vol. 23, pp. 381–389, 2000. View at Google Scholar
  7. D. Torley, G. A. Bellus, and C. S. Munro, “Genes, growth factors and acanthosis nigricans,” British Journal of Dermatology, vol. 147, no. 6, pp. 1096–1101, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. P. D. Cruz Jr. and J. A. Hud Jr., “Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans,” Journal of Investigative Dermatology, vol. 98, no. 6, pp. S82–S85, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. J. G. Leroy, L. Nuytinck, J. Lambert, J.-M. Naeyaert, and G. R. Mortier, “Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene,” American Journal of Medical Genetics Part A, vol. 143, no. 24, pp. 3144–3149, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. R. Berk, E. B. Spector, and S. J. Bayliss, “Familial acanthosis nigricans due to K650T FGFR3 mutation,” Archives of Dermatology, vol. 143, no. 9, pp. 1153–1156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Castro-Feijóo, L. Loidi, A. Vidal et al., “Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?” European Journal of Endocrinology, vol. 159, no. 3, pp. 243–249, 2008. View at Publisher · View at Google Scholar
  12. A. M. R. Downs and C. T. C. Kennedy, “Somatotrophin-induced acanthosis nigricans,” British Journal of Dermatology, vol. 141, no. 2, pp. 390–391, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Van Esch and J. P. Fryns, “Acanthosis nigricans in a boy with achondroplasia due to the classical Gly380Arg mutation in FGFR3,” Genetic Counseling, vol. 15, no. 3, pp. 375–377, 2004. View at Google Scholar · View at Scopus
  14. K. S. Alatzoglou, P. C. Hindmarsh, C. Brain, J. Torpiano, and M. T. Dattani, “Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 10, pp. 3959–3963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. T. Hertel, O. Eklöf, S. Ivarsson et al., “Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial,” Acta Paediatrica, vol. 94, no. 10, pp. 1402–1410, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Blomberg, E. M. Jeppesen, F. Skovby, and E. Benfeldt, “FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature,” Dermatology, vol. 220, no. 4, pp. 297–305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Prinos, T. Costa, A. Sommer, M. W. Kilpatrick, and P. Tsipouras, “A common FGFR3 gene mutation in hypochondroplasia,” Human Molecular Genetics, vol. 4, no. 11, pp. 2097–2101, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Mortier, L. Nuytinck, M. Craen, J.-P. Renard, J. G. Leroy, and A. De Paepe, “Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene,” Journal of Medical Genetics, vol. 37, no. 3, pp. 220–224, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. P. P. Deutz-Terlouw, M. Losekoot, C. M. Aalfs, R. C. M. Hennekam, and E. Bakker, “Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia,” Human Mutation, vol. 11, supplement 1, pp. S62–S65, 1998. View at Publisher · View at Google Scholar · View at Scopus